Ebos Group Limited · NZX:EBO
Ebos — Shareholder Meeting (October 2018)
22 slides from Ebos's shareholder meeting presentation, Oct 16, 2018
Slide 1: 96th Annual Meeting
For personal use only 96TH ANNUAL MEETING 16 October 2018
Slide 2: Disclaimer
DISCLAIMER The information in this presentation was prepared by EBOS Group Ltd with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or For personal use only reliabil
Slide 3: 2018 Annual Meeting: Chairman – Mr Mark Waller
For personal use only 2018 Annual Meeting Chairman – Mr Mark Waller
Slide 4: Agenda
AGENDA Welcome For personal use only Introducing members of the Board Presentations Mark Waller, Chairman John Cullity, Chief Executive Officer Business of meeting Conclusion 4
Slide 5: Board of Directors
BOARD OF DIRECTORS For personal use only Mark Waller Independent Chairman of Directors Appointed 1987 Appointed Chairman 2015 Elizabeth Coutts Stuart McGregor Sarah Ottrey Peter Williams Independent Non-executive Independent Non-executive Director Director Director Director Joined 2003 Joined 2013 J
Slide 6: FY18 Summary Results
FY18 SUMMARY RESULTS Constant FX For personal use only Reported Underlying NZ$m FY18 FY17 Var% Var%2 Revenue 7,609.5 7,625.9 (0.2%) (2.5%) EBITDA 272.4 234.4 16.2% 10.3% NPAT1 149.6 133.3 12.2% 5.5% Earnings per Share (cents) 98.5c 87.8c 12.1% 5.4% Total Dividends (cents) 68.5c 63.0c 8.7% Note 1: Ne
Slide 7: Years Post Symbion Deal
5 YEARS POST SYMBION DEAL We continue to deliver results whilst reinvesting for growth For personal use only Investments made (NZ$m) Results achieved 5 Year Underlying EBITDA 5 Year Underlying EPS $569m over NZ$m cents per share FY18 272.4 98.5 last 5 years FY18 FY17 241.4 FY17 91.3 5 Year 5 Year FY
Slide 8: Business Segment Overview
BUSINESS SEGMENT OVERVIEW Gross Operating Revenue (GOR) FY18 FY18 Revenue by country For personal use only 14% New 21% 86% Zealand 14% 79% Australia 5% 48% 8% FY18 GOR Mix FY18 EBITDA by country New 25% Zealand 18% 82% Australia Health Care Pharmacy Contract Logistics (Wholesale and retail) Animal C
Slide 9: EBOS Strategic Approach
EBOS STRATEGIC APPROACH Our Healthcare and Animal Care strategic focus is centred on For personal use only Leading Market Disciplined Capital Investing for Growth Positions Management Two types of investments: We aim to have positions of Cash generation to drive scale in the markets we operate sco
Slide 10: 2018 Annual Meeting: CEO – Mr John Cullity
For personal use only 2018 Annual Meeting CEO – Mr John Cullity
Slide 11: 2018 Strategic Highlights
2018 STRATEGIC HIGHLIGHTS Investments and New Business For personal use only Investments of $33.6m made in FY18 14.1% investment in ASX listed, MedAdvisor Ltd (October 2017). Australia’s leading digital medication management company. Acquisition of Gran’s Remedy (March 2018). New Zealand leading
Slide 12: 2019 Business & Investment Update
2019 BUSINESS & INVESTMENT UPDATE We have made an active start to the FY19 year For personal use only Previously announced – 2 July 2018 – Chemist Warehouse tender win In July 2018, EBOS was notified it won the tender to act as the exclusive third party distributor of pharmaceutical products to mo
Slide 13: Corporate Video
CORPORATE VIDEO The corporate video that will be shown at the Annual Meeting For personal use only can be viewed on the EBOS Group website at www.ebosgroup.com 13
Slide 14: FY18 Segment Performance: Healthcare
FY18 SEGMENT PERFORMANCE HEALTHCARE For personal use only Constant FX EBITDA increase of $27.1m or 10.4% NZ$m FY18 FY17 Var Var (constant FX): Revenue 7,197.6 7,202.7 (0.1%) (2.3%) Australia up 11.9% assisted by the full EBITDA 235.9 208.8 13.0% 10.4% year contributions of HPS (acquired June 2017)
Slide 15: FY18 Segment Performance: Animal Care
FY18 SEGMENT PERFORMANCE ANIMAL CARE For personal use only Constant FX EBITDA increase of $5.1m or 9.0% NZ$m FY18 FY17 Var Var (constant currency): Revenue 411.9 423.2 (2.7%) (5.1%) Black Hawk sales growth in Australia EBITDA 49.8 44.7 11.3% 9.0% of 23%. EBIT 46.2 41.2 12.2% 9.8% Earnings were n
Slide 16: FY19 Trading Update
FY19 TRADING UPDATE For personal use only We have made a solid start to the first quarter of FY19, with strong growth in Animal care and modest underlying growth in Healthcare attributable to increasingly competitive market dynamics. On the basis of our current trading performance, we expect the
Slide 17: 2018 Annual Meeting: Business of the Meeting
For personal use only 2018 Annual Meeting Business of the Meeting
Slide 18: Annual Report and Financial Statements
ITEM 1 Annual Report and Financial Statements For personal use only To consider and receive the annual report and the financial statements for the year ended 30 June 2018 and the audit report thereon. 18
Slide 19: Director re-election – Elizabeth Coutts
ITEM 2 Director re-election – Elizabeth Coutts For personal use only To consider the re-election of Elizabeth Coutts as a director of the Company. Elizabeth Coutts retires by rotation and being eligible offers herself for re-election. Elizabeth Coutts ONZM, BMS, CA Independent Director Elizabeth Cou
Slide 20: Director re-election – Peter Williams
ITEM 3 Director re-election – Peter Williams For personal use only To consider the re-election of Peter Williams as a director of the Company. Peter Williams retires by rotation and being eligible offers himself for re-election. Peter Williams Non-executive Director Peter Williams was appointed to t
Slide 21: Auditor fees and expenses
ITEM 4 Auditor fees and expenses For personal use only That the directors be authorised to fix the fees and expenses of Deloitte as the auditor of the Company. 21
Slide 22: Thank you for attending
Thank you for attending For personal use only Please join us for refreshments www.ebosgroup.com